Literature DB >> 33945799

Bioactive stigmastadienone from Isodon rugosus as potential anticholinesterase, α-glucosidase and COX/LOX inhibitor: In-vitro and molecular docking studies.

Yahya S Alqahtani1.   

Abstract

Natural product is a well-known source of bioactive compounds. Herein, a steroidal compound stigmasta-7,22-diene-3-one (stigmastadienone) has been isolated from Isodon rugosus. The potency of isolated compound has been tested for several in-vitro targets. The acetyl and butyrylcholinesterase assays were performed using Ellman's procedure. For the in-vitro antidiabetic potential, α-glucosidase inhibitory assay was performed. Similarly, the cyclo and lipoxygenase pathways were studied to find its potential role in the management of inflammation and analgesia. The 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) and hydrogen peroxide (H2O2) assays were performed for the antioxidant potentials. Docking studies were performed against acetylcholinesterase, cyclooxygenase and lipoxygenase targets. In anticholinesterase assays, stigmastadienone exhibited half-maximal inhibitory concentration (IC50) values of 13.52 and 11.53 μg/ml for acetyl and butyrylcholinesterase respectively. The observed IC50 values for that of galantamine were 6.07 and 4.42 μg/ml for acety and butyrylcholinesterase respectively. In inhibiting α-glucosidase enzyme, the compound showed mediocre IC50 of 109.40 μg/ml compared to the standard acarbose (7.60 μg/ml). The stigmastadienone proved to be an excellent inhibitor of cyclooxygenase 2 (COX-2) and 5-lipoxygenase (5-LOX) attaining IC50 values of 4.72 and 3.36 μg/ml respectively. The standard drugs IC50 values for COX-2 (celecoxib) and 5-LOX (montelukast) were 3.81 and 2.74 μg/ml respectively. The enzymatic activities of stigmastadienone were also supplemented with antioxidant results, specifically it was more dominant against DPPH and ABTS free radicals. Docking studies showed that only the carbonyl oxygen is able to form hydrogen bond interaction with the residues. In conclusions, the stigmastadienone has been isolated from Isodon rugosus for the first time. Moreover, the compound has been evaluated for several biochemical pathways which suggest its pharmacological role on the explored targets.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticholinesterase; Cyclooxygenase; Glucosidase; Isodon rugosus; Lipoxygenase; Stigmastadienone

Mesh:

Substances:

Year:  2021        PMID: 33945799     DOI: 10.1016/j.steroids.2021.108857

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  4 in total

1.  Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches.

Authors:  Mater H Mahnashi; Yahya S Alqahtani; Ali O Alqarni; Bandar A Alyami; Muhammad Saeed Jan; Muhammad Ayaz; Farhat Ullah; Umer Rashid; Abdul Sadiq
Journal:  BMC Complement Med Ther       Date:  2021-10-27

2.  Succinimide Derivatives as Antioxidant Anticholinesterases, Anti-α-Amylase, and Anti-α-Glucosidase: In Vitro and In Silico Approaches.

Authors:  Osama M Alshehri; Mater H Mahnashi; Abdul Sadiq; Rehman Zafar; Muhammad Saeed Jan; Farhat Ullah; Mohammed Ali Alshehri; Saleh Alshamrani; Elhashimi E Hassan
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-30       Impact factor: 2.650

3.  Prospective Application of Two New Pyridine-Based Zinc (II) Amide Carboxylate in Management of Alzheimer's Disease: Synthesis, Characterization, Computational and in vitro Approaches.

Authors:  Rehman Zafar; Humaira Naureen; Muhammad Zubair; Khadija Shahid; Muhammad Saeed Jan; Samar Akhtar; Hammad Ahmad; Wajeeha Waseem; Ali Haider; Saqib Ali; Muhammad Tariq; Abdul Sadiq
Journal:  Drug Des Devel Ther       Date:  2021-06-21       Impact factor: 4.162

4.  Acetylcholinesterase and monoamine oxidase-B inhibitory activities by ellagic acid derivatives isolated from Castanopsis cuspidata var. sieboldii.

Authors:  Jong Min Oh; Hyun-Jae Jang; Myung-Gyun Kang; Soobin Song; Doo-Young Kim; Jung-Hee Kim; Ji-In Noh; Jong Eun Park; Daeui Park; Sung-Tae Yee; Hoon Kim
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.